Evidence map›Paper›PMID 25161186›Full record

ArticlemBio2014

Origin and evolution of European community-acquired methicillin-resistant Staphylococcus aureus.

Marc Stegger, Thierry Wirth, Paal S Andersen, Robert L Skov, Anna De Grassi, Patricia Martins Simões, Anne Tristan, Andreas Petersen, Maliha Aziz, Kristoffer Kiil and 19 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.

  1. Methicillin-ResistantToxins · 2020
    Pooled it
  2. Review
  3. Spread of the FAR-MRSA clone, a fusidic acid- and meticillin-resistantEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  4. Review
  5. Community-acquired methicillin-resistantFrontiers in medicine · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Antimicrobial resistance and clonality ofFrontiers in microbiology · 2023
    Article
  11. Characterisation of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023
    Article
  12. Diversity and Dissemination of Methicillin-ResistantTropical medicine and infectious disease · 2022
    Review
  13. Phylodynamic signatures in the emergence of community-associated MRSA.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  14. Whole-Genome Sequencing ofMicrobiology spectrum · 2022
    Article
  15. The New Precision Stewards?Journal of personalized medicine · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 19 institutions in 13 countries.

Marc Steggermtg@ssi.dk.
Thierry Wirth
Paal S Andersen
Robert L SkovMicrobiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.
Anna De GrassiDépartement Systématique et Evolution, Muséum National d'Histoire Naturelle, Paris, France.
Patricia Martins Simões
Anne Tristan
Andreas PetersenMicrobiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.
Maliha Aziz
Kristoffer KiilMicrobiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.
Ivana CirkovićInstitute of Microbiology and Immunology, Medical Faculty, University of Belgrade, Belgrade, Serbia.
Edet E UdoDepartment of Microbiology, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
Rosa del CampoServicio de Microbiología, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Jaana Vuopio-VarkilaNational Institute for Health and Welfare, Helsinki, Finland.
Norazah AhmadInstitute for Medical Research, Kuala Lumpur, Malaysia.
Sima TokajianGenomics and Proteomics Research Laboratory, Department of Biology, Lebanese American University, Byblos, Lebanon.
Georg PetersInstitute of Medical Microbiology, University Hospital Münster, Münster, Germany.
Frieder SchaumburgInstitute of Medical Microbiology, University Hospital Münster, Münster, Germany.
Barbro Olsson-LiljequistSwedish Institute for Infectious Disease Control, Solna, Sweden.
Michael GivskovDepartment of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Elizabeth E DriebePathogen Genomics Division, Translational Genomics Research Institute, Flagstaff, Arizona, USA.
Henrik E VighDepartment of Anthropology, University of Copenhagen, Copenhagen, Denmark.
Adebayo ShittuDepartment of Microbiology, Obafemi Awolowo University, Ile-Ife, Nigeria.
Nadjia Ramdani-BougessaDepartment of Bacteriology, Centre Hispitalo-universitaire Mustapha-Pacha, Algiers, Algeria.
Jean-Philippe Rasigade
Lance B Price
Francois Vandenesch
Anders R LarsenMicrobiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.
Frederic Laurent
Statens Serum Institut · DKInserm · FRGeorge Washington University · USTranslational Genomics Research Institute · USUniversity Hospital Münster · DEUniversity of Copenhagen · DKCentre International de Recherche en Infectiologie · FRÉcole Pratique des Hautes Études · FRFinnish Institute for Health and Welfare · FIHôpital Mustapha Pacha · DZHospices Civils de Lyon · FRHospital Universitario Ramón y Cajal · ESInstitut de Systématique, Évolution, Biodiversité · FRInstitute for Medical Research · MYKuwait University · KWLebanese American University · LBObafemi Awolowo University · NGSwedish Institute · SEUniversity of Belgrade · RS

Funding

Rapid Emergence of Livestock-associated MRSA ST398: Host-adaptation & VirulenceR01AI101371 · NIAID · TRANSLATIONAL GENOMICS RESEARCH INST · PI PRICE, LANCE BRADLEY · 2013 to 2016
$1.6M
NIAID NIH HHS R01 AI101371
6 · The paper itself

Abstract

unlabelledCommunity-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) was recognized in Europe and worldwide in the late 1990s. Within a decade, several genetically and geographically distinct CA-MRSA lineages carrying the small SCCmec type IV and V genetic elements and the Panton-Valentine leukocidin (PVL) emerged around the world. In Europe, the predominant CA-MRSA strain belongs to clonal complex 80 (CC80) and is resistant to kanamycin/amikacin and fusidic acid. CC80 was first reported in 1993 but was relatively rare until the late 1990s. It has since been identified throughout North Africa, the Middle East, and Europe, with recent sporadic reports in sub-Saharan Africa. While strongly associated with skin and soft tissue infections, it is rarely found among asymptomatic carriers. Methicillin-sensitive S. aureus (MSSA) CC80 strains are extremely rare except in sub-Saharan Africa. In the current study, we applied whole-genome sequencing to a global collection of both MSSA and MRSA CC80 isolates. Phylogenetic analyses strongly suggest that the European epidemic CA-MRSA lineage is derived from a PVL-positive MSSA ancestor from sub-Saharan Africa. Moreover, the tree topology suggests a single acquisition of both the SCCmec element and a plasmid encoding the fusidic acid resistance determinant. Four canonical SNPs distinguish the derived CA-MRSA lineage and include a nonsynonymous mutation in accessory gene regulator C (agrC). These changes were associated with a star-like expansion into Europe, the Middle East, and North Africa in the early 1990s, including multiple cases of cross-continent imports likely driven by human migrations. IMPORTANCE: With increasing levels of CA-MRSA reported from most parts of the Western world, there is a great interest in understanding the origin and factors associated with the emergence of these epidemic lineages. To trace the origin, evolution, and dissemination pattern of the European CA-MRSA clone (CC80), we sequenced a global collection of strains of the S. aureus CC80 lineage. Our study determined that a single descendant of a PVL-positive methicillin-sensitive ancestor circulating in sub-Saharan Africa rose to become the dominant CA-MRSA clone in Europe, the Middle East, and North Africa. In the transition from a methicillin-susceptible lineage to a successful CA-MRSA clone, it simultaneously became resistant to fusidic acid, a widely used antibiotic for skin and soft tissue infections, thus demonstrating the importance of antibiotic selection in the success of this clone. This finding furthermore highlights the significance of horizontal gene acquisitions and underscores the combined importance of these factors for the success of CA-MRSA.

Indexed as

Evolution, MolecularGenes, BacterialAfrica, NorthernAnti-Bacterial AgentsBacterial ProteinsBacterial ToxinsBacterial Typing TechniquesChromosome MappingCloning, MolecularDNA, BacterialDrug Resistance, BacterialEuropeExotoxinsLeukocidinsMethicillin-Resistant Staphylococcus aureusMiddle EastAgrC protein, StaphylococcusAnti-Bacterial AgentsBacterial ProteinsBacterial ToxinsDNA, BacterialExotoxinsLeukocidinsPanton-Valentine leukocidinProtein Kinases

Identifiers

PMID25161186
PMCPMC4173770
OpenAlexW1986374905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.